Codex DNA, Inc. (NASDAQ:DNAY) Sees Significant Decrease in Short Interest

Codex DNA, Inc. (NASDAQ:DNAYGet Rating) was the target of a large decline in short interest in April. As of April 15th, there was short interest totalling 1,370,000 shares, a decline of 30.8% from the March 31st total of 1,980,000 shares. Approximately 15.8% of the shares of the stock are short sold. Based on an average trading volume of 343,900 shares, the short-interest ratio is currently 4.0 days.

Several analysts have recently weighed in on DNAY shares. KeyCorp decreased their target price on shares of Codex DNA from $30.00 to $8.00 and set an “overweight” rating on the stock in a research report on Monday, March 28th. Zacks Investment Research lowered shares of Codex DNA from a “hold” rating to a “sell” rating in a research report on Friday, April 22nd. Finally, Cowen started coverage on shares of Codex DNA in a research report on Wednesday, March 2nd. They set a “buy” rating on the stock.

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. lifted its holdings in Codex DNA by 66.8% during the 3rd quarter. BlackRock Inc. now owns 333,471 shares of the company’s stock valued at $3,712,000 after purchasing an additional 133,512 shares during the last quarter. Strs Ohio raised its stake in shares of Codex DNA by 1,150.0% in the fourth quarter. Strs Ohio now owns 22,500 shares of the company’s stock worth $243,000 after acquiring an additional 20,700 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of Codex DNA by 33.4% in the third quarter. Franklin Resources Inc. now owns 732,900 shares of the company’s stock worth $8,157,000 after acquiring an additional 183,700 shares during the last quarter. Deutsche Bank AG bought a new position in shares of Codex DNA in the third quarter worth about $50,000. Finally, Bank of America Corp DE raised its stake in shares of Codex DNA by 973.6% in the fourth quarter. Bank of America Corp DE now owns 5,454 shares of the company’s stock worth $59,000 after acquiring an additional 4,946 shares during the last quarter. 31.49% of the stock is owned by hedge funds and other institutional investors.

Shares of DNAY stock opened at $3.70 on Friday. Codex DNA has a 12-month low of $3.67 and a 12-month high of $25.70. The firm has a 50-day moving average price of $6.81 and a 200 day moving average price of $7.84. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.57 and a quick ratio of 9.33.

Codex DNA (NASDAQ:DNAYGet Rating) last announced its quarterly earnings results on Tuesday, March 22nd. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The company had revenue of $3.08 million for the quarter, compared to analysts’ expectations of $3.83 million. On average, research analysts predict that Codex DNA will post -2.11 EPS for the current year.

About Codex DNA (Get Rating)

Codex DNA, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis.

Further Reading

Receive News & Ratings for Codex DNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codex DNA and related companies with MarketBeat.com's FREE daily email newsletter.